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JOURNAL OF HEPATOLOGYin advance
To the Editor:
We would like to thank Ganapathy-Kanniappan et al., for relating
to our work to suggest an interesting hypothesis for the origin of
hepatocellular carcinoma (HCC). Based on the recent and histor-
ical ﬁndings that HCC is associated with elevated glycolysis [1,2]
they propose an interesting hypothesis that metabolic adapta-
tions in early stages of liver cirrhotic hepatocytes could be linked
to the origin of tumorigenesis in liver and that end-stage failing
cirrhotic hepatocytes undergoes metabolic adaptations leading
to HCC. However, the mechanistic links between liver cirrhosis
and HCC are unclear and identiﬁcation of pathways connecting
both remains elusive. The focus of our recent work was the study
of adaptive energy metabolic changes during liver cirrhosis to
understand hepatic failure in the terminal stages of chronic injury
[3]. Even though the letter to the editor from Ganapathy-Kan-
niappan et al., is not completely related to the study we designed
it is recognized that liver cirrhosis is considered as a precursor to
HCC.
In addition to hepatocytes, it is important to consider the role
of the tumor microenvironment in regulating the metabolism of
cancer cells. Recent studies have shown that cells in the tumor
microenvironment generate energy rich metabolites (e.g., lactate
beta-hydroxybutyrate) that are used by cancer cells for meeting
their energetic demand through mitochondrial tricarboxylic acid
cycle [4,5]. Based on the compelling recent results [6], one possi-
bility is that microenvironment may induce metabolic transfor-
mations in early cirrhotic hepatocytes and when in contact
with stromal cells to sustain their nutrient demand. Early cir-
rhotic hepatocytes may alter the surrounding cells metabolic
phenotype to secrete high-energy metabolites for their energetic
requirements. Metabolic alterations and adaptations are thus an
exciting area of investigation.
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manuscript.Cost-effectiveness of upcoming treatments for hepatitis C: We need
to get the models right
To the Editor:
We read with great interest the recent article on cost-effective-
ness of current and future treatments of patients with HCV
genotype 1 by Younossi and colleagues [1]. Although the authors
explore a very pertinent issue regarding treatment decisions in
such patients, there are certain aspects that somewhat decrease
the validity of their ﬁndings.
Firstly, the authors assume that the health-related utility/
quality of life is similar to all patients with HCV infection
irrespective of ﬁbrosis stage. The critical question is whether
patients with F0/F1 could be left without treatment. There is a
bias favoring a treat-all strategy if higher utilities are not ascribed
to patients with F0/F1 [2].
Secondly, the SVR rates of the all-oral therapy combination
are unclear and sourced from abstract publications in 2012. With
huge steps in HCV treatment since then, we would expect more
up to date source data. Moreover, we would favor a more
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